Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate how OSI-906 compares to Topotecan in trying to slow
down the growth and/or progression of the tumors of participants with relapsed or recurrent
Small Cell Lung Cancer.
This study also plans to find out what effects, good or bad (side effects), OSI-906 has on
participants and or Small Cell Lung Cancer. The study will also investigate if some proteins
measured in the blood or tumor and some imaging features obtained from computed tomography
(CT) scans can help predict whether OSI-906 or topotecan will be effective against Small Cell
Lung Cancer.